Mumbai, Baltimore: Global pharma major Lupin Limited (Lupin) today announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen® Tablets, 250 mg, of Mylan Specialty, L.P., and indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP, 250 mg (RLD: Depen®) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).

About Lupin Limited

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. For the nine months ended December 31, 2020, the Company invested 9.8% of its revenues on research and development.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on

Twitter: https://twitter.com/LupinGlobal
LinkedIn: https://www.linkedin.com/company/lupin
Facebook: http://www.facebook.com/LupinWorld/